| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 3 securities · may seek to influence control | ||||||
|
Trevi Therapeutics, Inc.
13D/A
TRVI · 89532M101
|
10.5% |
5/7/2026
Event 5/5/2026
|
||||
| New Enterprise Associates 16, L.P. | 10.5% | |||||
| NEA Partners 16, L.P. | 10.5% | |||||
| Nea 16 GP, LLC | 10.5% | |||||
| NEA 18 Venture Growth Equity, L.P. | 10.5% | |||||
| NEA Partners 18 VGE, L.P. | 10.5% | |||||
| Nea 18 Vge GP, LLC | 10.5% | |||||
| Forest Baskett | 9.8% | |||||
| Ali Behbahani | 10.5% | |||||
| Carmen Chang | 10.5% | |||||
| Anthony A. Florence, Jr. | 10.5% | |||||
| Mohamad H. Makhzoumi | 10.5% | |||||
| Scott D. Sandell | 10.5% | |||||
| Paul Walker | 10.5% | |||||
|
Marker Therapeutics, Inc.
13D/A
MRKR · 57055L206
|
9.9% |
11/17/2025
Event 11/13/2025
|
||||
| New Enterprise Associates 16, L.P. | 9.9% | |||||
| NEA Partners 16, L.P. | 9.9% | |||||
| Nea 16 GP, LLC | 9.9% | |||||
| Forest Baskett | 9.9% | |||||
| Ali Behbahani | 9.9% | |||||
| Carmen Chang | 9.9% | |||||
| Anthony A. Florence, Jr. | 9.9% | |||||
| Mohamad H. Makhzoumi | 9.9% | |||||
| Scott D. Sandell | 9.9% | |||||
| Paul Walker | 9.9% | |||||
|
Allakos Inc.
13D/A
ALLK · 01671P100
|
0% |
5/16/2025
Event 5/15/2025
|
||||
| New Enterprise Associates 16, L.P. | 0% | |||||
| NEA Partners 16, L.P. | 0% | |||||
| Nea 16 GP, LLC | 0% | |||||
| NEA 18 Venture Growth Equity, L.P. | 0% | |||||
| NEA Partners 18 VGE, L.P. | 0% | |||||
| Nea 18 Vge GP, LLC | 0% | |||||
| Ali Behbahani | 0% | |||||
| Carmen Chang | 0% | |||||
| Anthony A. Florence, Jr. | 0% | |||||
| Mohamad H. Makhzoumi | 0% | |||||
| Scott D. Sandell | 0% | |||||
| Peter W. Sonsini | 0% | |||||
| Paul Walker | 0% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.